ENvue Medical, Inc. FEED
Nasdaq · XNAS · stock · Orthopedic, Prosthetic & Surgical Appliances & Supplies
Chart by TradingView
2/9
Piotroski F — financial health
-6.2
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $2.6M | -$18.2M | $153,000 | -$9.4M | $33.5M |
| 2024 | $2.6M | -$3.7M | $1.5M | -$2.5M | $627,000 |
| 2023 | $2.3M | -$3.7M | $1.5M | -$3.6M | $4.0M |
| 2022 | $752,000 | -$5.4M | $167,000 | -$7.0M | $3.2M |
| 2021 | $1.7M | -$14.3M | $770,000 | -$4.4M | $6.3M |
| 2020 | $623,000 | -$4.3M | $214,000 | -$3.4M | $2.4M |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -6.2 (distress)
- Working capital / assets 0.015
- Retained earnings / assets -2.2
- EBIT / assets -0.557
- Equity / liabilities 4.392
Source: SEC EDGAR filings · CIK 0001326706 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.